Cyclerion Therapeutics Announces Praliciguat Topline Phase 2 Results in Diabetic Nephropathy

Stock Information for Cyclerion Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cyclerion Therapeutics Inc.

Cyclerion Appoints Regina Graul, Ph.D., as President
Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator
Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets
Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement
Cyclerion Announces Reverse Stock Split
Cyclerion Announces Corporate Updates and Q1 2023 Financial Results
Cyclerion Announces Definitive Agreement for Zagociguat and CY3018
Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.